Comparative evaluation of a new chemiluminiscent assay and an ELISA for the detection of IgM against measles

Abstract

Background: The primary test for the laboratory confirmation of measles is immunoglobulin M (IgM) serology. It is therefore important to evaluate new commercial measles IgM immunoassays to ensure high-quality measles diagnostic testing. The purpose of this study was to evaluate the diagnostic performance of LIAISON IgM measles (DiaSorin, Saluggia, Italy), a new automated chemiluminescence immunoassay (CLIA), in comparison with enzyme immunoassay (EIA) Enzygnost (Siemens, Marburg, Germany).

Methods: Sensitivity was examined using a panel of measles laboratory confirmed sera; specificity was addressed by testing sera from healthy populations and subjects with infections that may interfere with measles IgM serology.

Results: The diagnostic performances of the two assays were very similar: both Enzygnost EIA and LIAISON CLIA performed with a sensitivity of 93.7% and 98.8%, whereas the specificity was 96.8% and 97.9%, respectively.

Conclusion: We concluded that LIAISON IgM measles can be a good alternative to the other immunoassay for laboratory measles confirmation.